Human NKG2D / CD314 Protein, Fc Tag (HPLC-verified)
分子別名(Synonym)
NKG2D,CD314,KLRK1,NK cell receptor D
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human NKG2D Protein, Fc Tag (NKD-H5265) is expressed from human 293 cells (HEK293). It contains AA Ile 73 - Val 216 (Accession # P26718-1).
Predicted N-terminus: Pro
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a human IgG1 Fc tag at the N-terminus.
The protein has a calculated MW of 43.1 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
NKG2D是一種跨膜蛋白,屬于C型凝集素樣受體CD94/NKG2家族,也稱(chēng)為KLRK1、CD314、D12S2489E、KLR和殺傷細(xì)胞凝集素樣受體K1。NKG2D本身形成同二聚體,其外結(jié)構(gòu)域用于配體結(jié)合。NKG2D是檢測(cè)和消除轉(zhuǎn)化和感染細(xì)胞的主要識(shí)別受體,因?yàn)槠渑潴w在細(xì)胞應(yīng)激期間被誘導(dǎo),無(wú)論是感染還是基因組應(yīng)激,如癌癥。在NK細(xì)胞中,NKG2D作為一種激活受體,其本身能夠引發(fā)細(xì)胞毒性。NKG2D對(duì)CD8+T細(xì)胞的作用是發(fā)送共刺激信號(hào)以激活它們。
關(guān)鍵字: NKG2D;NKG2D蛋白;NKG2D重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。